Matrixyl Serum 3000

Matrixyl Serum 3000 is a ready-to-use aqueous serum built around the 3000-type matrikine pairing: palmitoyl tripeptide-1 (Pal-Gly-His-Lys) and palmitoyl tetrapeptide-7 (Pal-Gly-Gln-Pro-Arg). Both are lipidated signal peptides, meaning a palmitic acid chain is attached to the peptide N-terminus to raise lipophilicity and improve partitioning into a lipid-rich barrier that bare hydrophilic peptides cross poorly.

The two peptides carry different parent sequences and are studied for different reasons. GHK is the tripeptide identified in human plasma in the 1970s and studied extensively in matrix and copper-binding research; GQPR derives from immunoglobulin G and appears in work on cytokine signalling in dermal models. Combining a matrix-signalling matrikine with an inflammation-associated fragment is the rationale behind the 3000-type complex, and it is why comparative studies usually test each peptide separately as well as together.

This differs from our Matrixyl vial, which supplies palmitoyl pentapeptide-4 (Pal-KTTKS) as lyophilized powder for a laboratory to formulate itself. The serum removes that step: it is a low-viscosity aqueous vehicle in a 30 mL bottle, prepared with peptide inputs released at high HPLC purity with lot-matched documentation. It is supplied for laboratory and formulation research and is not a licensed cosmetic or drug product.

Because this is supplied at a stated strength, the question is rarely how much diluent to add — it is what that strength looks like in the units your method is written in. Convert mcg to mg, mL to µL and back with the unit converter.